We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock
LUMO

Delisted

LUMO was delisted on the 11th of December, 2024.

Back to rankings

87 hedge funds and large institutions have $19.5M invested in Lumos Pharma, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more call options, than puts

Call options by funds: $35K | Put options by funds: $34K

5% less funds holding

Funds holding: 92 → 87 (-5)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

28% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 25

43% less capital invested

Capital invested by funds: $34M → $19.5M (-$14.5M)

Holders
87
Holders Change
-5
Holders Change %
-5.43%
% of All Funds
1.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
18
Reduced
25
Closed
19
Calls
$35K
Puts
$34K
Net Calls
+$1K
Net Calls Change
+$38K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.42M
2
AFM
Anson Funds Management
Texas
+$552K
3
OAM
Oxford Asset Management
United Kingdom
+$532K
4
PAM
Panagora Asset Management
Massachusetts
+$251K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$175K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.48M
2
BlackRock
BlackRock
New York
-$753K
3
Axa
Axa
France
-$614K
4
CS
Candriam SCA
Luxembourg
-$593K
5
TCM
Tekla Capital Management
Massachusetts
-$490K
Name Holding Trade Value Shares
Change 		Change in
Stake
TA
26
Teachers Advisors
New York
$81K – – –
PPA
27
Parametric Portfolio Associates
Washington
$81K +$104K +5,890 New
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$81K +$105K +5,940 New
BIM
29
Bogle Investment Management
Massachusetts
$80K -$11K -622 -10%
AllianceBernstein
30
AllianceBernstein
Tennessee
$79K – – –
LA
31
LexAurum Advisors
Kansas
$79K – – –
Charles Schwab
32
Charles Schwab
California
$75K – – –
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$61K +$23.1K +1,314 +41%
Deutsche Bank
34
Deutsche Bank
Germany
$56K -$81.7K -4,641 -52%
JG
35
Jefferies Group
New York
$56K +$40.9K +2,320 +129%
State of Wisconsin Investment Board
36
State of Wisconsin Investment Board
Wisconsin
$45K +$24.5K +1,389 +74%
Goldman Sachs
37
Goldman Sachs
New York
$37K -$109K -6,209 -70%
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$33K – – –
State Board of Administration of Florida Retirement System
39
State Board of Administration of Florida Retirement System
Florida
$33K – – –
PP
40
Paloma Partners
Connecticut
$30K +$39.1K +2,222 New
AIG
41
American International Group
New York
$29K -$299 -17 -0.8%
California Public Employees Retirement System
42
California Public Employees Retirement System
California
$28K – – –
UBS Group
43
UBS Group
Switzerland
$28K +$27.3K +1,550 +316%
AG
44
Advisor Group
Arizona
$26K – – –
Barclays
45
Barclays
United Kingdom
$26K +$6.48K +368 +23%
ARTA
46
A.R.T. Advisors
New York
$26K +$33.1K +1,879 New
Citigroup
47
Citigroup
New York
$23K -$32K -1,818 -52%
Citadel Advisors
48
Citadel Advisors
Florida
$22K -$60.7K -3,447 -69%
CS
49
Credit Suisse
Switzerland
$20K +$25.6K +1,456 New
FAM
50
Fenimore Asset Management
New York
$19K – – –
1
2
3 4 5

LUMO Hedge Fund Activity: Q4 2018 in Review

87 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2018, worth a combined $19.5M — down 43% from $34M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of LUMO and 15 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 18 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.42M. The largest seller was Vanguard Group, cutting an estimated $1.48M.

  • 87 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2018, down from 92 in Q3 2018.
  • Funds reported $19.5M of Lumos Pharma, Inc. Common Stock stock for Q4 2018, down 43% quarter-over-quarter.
  • 15 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2018 and 19 closed out, a net change of -4 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2018 was Renaissance Technologies, an estimated $1.42M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q4 2018 was Vanguard Group, an estimated $1.48M sold.

Based on aggregated 13F filings for Q4 2018.